Effect of long-term ACE-inhibitor therapy in elderly vascular disease patients

European Heart Journal

Volumn 28, Issue 11, 2007, Pages 1382-1388

  Gianni, Monica ^a,b   Bosch, Jackie ^b   Pogue, Janice ^b   Probstfield, Jeffrey ^c   Dagenais, Gilles ^d   Yusuf, Salim ^b,e   Lonn, Eva ^b,e,f  

^a UNIVERSITY OF INSUBRIA   (Italy)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITÉ LAVAL   (Canada)

^e MCMASTER UNIVERSITY   (Canada)

^f HAMILTON HEALTH SCIENCES   (Canada)

Author keywords

ACE inhibitor; Age; Cardiovascular disease; Myocardial infarction; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; PLACEBO; RAMIPRIL;

AGED; ANGIONEUROTIC EDEMA; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GERIATRIC PATIENT; GROUPS BY AGE; HAZARD ASSESSMENT; HEART EJECTION FRACTION; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; KIDNEY DYSFUNCTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OPEN STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; SINGLE BLIND PROCEDURE; STROKE; VASCULAR DISEASE;

AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; LONG-TERM CARE; MALE; MIDDLE AGED; RAMIPRIL; RISK FACTORS; SINGLE-BLIND METHOD; TREATMENT OUTCOME; WITHHOLDING TREATMENT;

EID: 34548399417     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehm017     Document Type: Article

References (18)

1. Anderson RN, Smith BL. Deaths: leading causes for 2002. Natl Vital Stat Rep 2005;53:1-89.
2. De Backer G, Ambrosione E, Borch-Johnson K, Brotons C, Cifkova R, Dallongeville J, Ebrahim S, Faergeman O, Graham I, Mancia G, Manger Cats V, Orth-Gomer K, Perk J, Pyorala K, Rodicio JL, Sans S, Sansoy V, Sechtem U, Silber S, Thomsen T, Wood D, for the Third Joint Force of European other Societies on Cardiovascular Disease Prevention in Clinical Practice. European guidelines on cardiovascular disease prevention in clinical practice. Eur J Cardiovasc Prev Rehabil 2003;10(Suppl. 1):S1-S78.
3. Califf R, Cherniack R, Detre KM, Williams G, Wittes J, Friedman L, Roth C, Savage PJ. Recommendations from NHLBI Workshop. Improving Design and Conduct of Clinical Trials. www.nhlbi.nih.gov;.nhlbi.nih.gov (September 2006).
4. Wing LM, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GL, Johnston CI, McNeil JJ, Macdonald GJ, Marley JE, Morgan TO, West MJ, Second Australian National Blood Pressure Study Group. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003;348:583-592.
5. Ratnasabapathy Y, Lawes CM, Anderson CS. The Perindopril Protection Against Recurrent Stroke Study (PROGRESS): clinical implications for older patients with cerebrovascular disease. Drugs Aging 2003;20:241- 251.
6. Masoudi FA, Rathore SS, Wang Y, Havranek EP, Curtis JP, Foody JAF, Krumholz HM. National patterns of use and effectiveness of angiotensin- converting enzyme inhibitors in older patients with heart failure and left ventricular systolic dysfunction. Circulation 2004;110:724-731.
7. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-153.
8. Fox KM, EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-788.
9. Dagenais RD, Pogue J, Fox K, Simoons M, Yusuf S. Angiotensin-converting enzyme inhibitors in stable vascular disease without left ventricular dysfunction or heart failure: a combined analysis of three trials. Lancet 2006;368:581-588.
10. Braunwald E, Domanski MJ, Fowler SE, Geller NL, Gersh BJ, Hsia J, Pfeffer MA, Rice MM, Rosenberg YD, Rouleau JL, PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004;351:2058-2068.
11. Lonn EM, Yusuf S, Jha P, Montague TJ, Teo KK, Benedict CR, Pitt B. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 1994;90:2056-2069.
12. Lonn E, Gerstein HC, Smieja M, Mann JFE, Yusuf S. Mechanism of cardiovascular risk reduction with ramipril: insights from HOPE and HOPE substudies. Eur Heart J 2003;5(Suppl. A):A43-A48.
13. Lonn E S, Dzavik V, Doris I, Yi Q, Smith S, Moore-Cox A, Bosch J, Riley WA, Teo KK, for the SECURE Investigators. Effects of ramipril and of vitamin E on atherosclerosis: results of the prospective randomized Study to Evaluate Carotid Ultrasound changes in patients treated with Ramipril and vitamin E (SECURE). Circulation 2001;103:919-925.
14. Lonn E, Shaikholeslami R, Yi Q, Bosch J, Sullivan, Tanser P, Magi A, Yusuf S. Effects of ramipril on left ventricular mass and function in cardiovascular patients with controlled blood pressure and with preserved left ventricular ejection fraction: a substudy of the Heart Outcomes Prevention Evaluation (HOPE) Trial. J Am Coll Cardiol 2004;43:2200-2206.
15. Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989;321:868-873.
16. Mann J, Gerstein H, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001;134:629-636.
17. Ko DT, Mamdani M, Alter DA. Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox. J Am Med Assoc 2004;291:1864-1870.
18. Ramsay SE, Morris RW, Papacosta O, Lennon LT, Thomas MC, Whincup PH. Secondary prevention of coronary heart disease in older British men: extent of inequalities before and after implementation of the National Service Framework. J Public Health Med 2005;27:338-343.